FDA approves world's first mRNA seasonal flu vaccine from Moderna

The US Food and Drug Administration has approved Moderna's mRNA-based seasonal flu vaccine, the first of its kind in the world. The approval marks a significant milestone in vaccine technology and is part of Moderna's strategy to expand beyond its COVID-19 business. The move opens the door to broader use of mRNA technology for seasonal infectious diseases.